☰

David H. Aggen, Ph.D. - Publications

Affiliations: 
2010 University of Illinois, Urbana-Champaign, Urbana-Champaign, IL 
Area:
Biochemistry, Immunology, Molecular Biology
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Dallos M, Aggen DH, Hawley J, Lim EA, Stein MN, Kelly WK, Nanus DM, Drake CG. A randomized phase Ib/II study of nivolumab with or without BMS-986253 in combination with a short course of ADT in men with castration-sensitive prostate cancer (MAGIC-8). Journal of Clinical Oncology. 37: TPS329-TPS329. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps329  0.324
2019 Aggen DH, Ghasemzadeh A, Mao W, Chowdhury N, Chaimowitz M, Hawley J, Wang V, Dallos M, Zhang C, Li H, Guo XV, Drake CG. Preclinical development of combination therapy targeting the dominant cytokine interleukin-1β for renal cell carcinoma. Journal of Clinical Oncology. 37: e14237-e14237. DOI: 10.1200/Jco.2019.37.15_Suppl.E14237  0.343
2019 Dallos M, Obradovic A, Chowdhury N, Lopez Bujanda Z, Aggen DH, Hawley J, Rathkopf DE, Drake CG. Human prostate cancer immune phenotypes after androgen deprivation therapy. Journal of Clinical Oncology. 37: 5083-5083. DOI: 10.1200/Jco.2019.37.15_Suppl.5083  0.324
2019 Chowdhury N, Obradovic A, Aggen D, Wang V, Guo X, DeCastro GJ, Ding H, Califano A, Drake CG. Abstract 1476: Decoding the immunologic landscape of human clear cell renal carcinoma Cancer Research. 79: 1476-1476. DOI: 10.1158/1538-7445.Sabcs18-1476  0.447
2019 Wang* V, Obradovic A, Chowdhury N, Aggen D, Bush E, Decastro GJ, Anderson CB, McKiernan JM, Ding H, Sims P, Califano A, Drake CG. MP21-01 SINGLE CELL TRANSCRIPTIONAL PROFILING OF IMMUNE POPULATIONS WITHIN RENAL CELL CARCINOMA TUMOR MICROENVIRONMENT Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555529.56881.26  0.424
2017 Schmitt TM, Aggen DH, Ishida-Tsubota K, Ochsenreither S, Kranz DM, Greenberg PD. Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro. Nature Biotechnology. PMID 29106410 DOI: 10.1038/Nbt.4004  0.759
2014 Stone JD, Harris DT, Soto CM, Chervin AS, Aggen DH, Roy EJ, Kranz DM. A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunology, Immunotherapy : Cii. 63: 1163-76. PMID 25082071 DOI: 10.1007/S00262-014-1586-Z  0.822
2013 Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, Greenberg PD. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood. 122: 348-56. PMID 23673862 DOI: 10.1182/Blood-2013-01-478164  0.81
2013 Schmitt TM, Greenberg PD, Aggen DH, Kranz D, Ochsenreither S. Abstract PR12: Early TCRα expression during T cell development for the generation of enhanced-affinity TCRs for TCR gene therapy. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-Pr12  0.684
2013 Greenberg PD, Ochsenreither S, Schmitt T, Aggen D, Kranz D, Wolfl M, Kuball J, Majeti R, Weissman I, Stromnes I, Schietinger A, Ragnarsson G, Yee C, Bar M, Chapuis A. Abstract IA1: T cells vs. tumor cells: Arming/deploying T cells for a successful battle. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-Ia1  0.752
2012 Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology. 1: 863-873. PMID 23162754 DOI: 10.4161/Onci.20592  0.774
2012 Stone JD, Chervin AS, Aggen DH, Kranz DM. T cell receptor engineering. Methods in Enzymology. 503: 189-222. PMID 22230570 DOI: 10.1016/B978-0-12-396962-0.00008-2  0.811
2012 Aggen DH, Chervin AS, Schmitt TM, Engels B, Stone JD, Richman SA, Piepenbrink KH, Baker BM, Greenberg PD, Schreiber H, Kranz DM. Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains. Gene Therapy. 19: 365-74. PMID 21753797 DOI: 10.1038/Gt.2011.104  0.756
2011 Stone JD, Aggen DH, Chervin AS, Narayanan S, Schmitt TM, Greenberg PD, Kranz DM. Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8. Journal of Immunology (Baltimore, Md. : 1950). 186: 5193-200. PMID 21451107 DOI: 10.4049/Jimmunol.1003755  0.767
2011 Aggen DH, Chervin AS, Insaidoo FK, Piepenbrink KH, Baker BM, Kranz DM. Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors. Protein Engineering, Design & Selection : Peds. 24: 361-72. PMID 21159619 DOI: 10.1093/Protein/Gzq113  0.774
2009 Richman SA, Aggen DH, Dossett ML, Donermeyer DL, Allen PM, Greenberg PD, Kranz DM. Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments. Molecular Immunology. 46: 902-16. PMID 18962897 DOI: 10.1016/J.Molimm.2008.09.021  0.761
2008 Chervin AS, Aggen DH, Raseman JM, Kranz DM. Engineering higher affinity T cell receptors using a T cell display system. Journal of Immunological Methods. 339: 175-84. PMID 18854190 DOI: 10.1016/J.Jim.2008.09.016  0.82
Show low-probability matches.